Drug Trial Radar · NCT04534205
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
358
Actual
Start
Jan 7, 2021
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. Part B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Patients included in the Safety Run-In Phase of the trial (Part A) will not be randomized to Part B and will continue on-trial treatment (BNT113 plus pembrolizumab) within Part A. For Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial. Patients will be treated with BNT113 in combination with pembrolizumab or with pembrolizumab monotherapy for approximately up to 24 months.
Conditions
- Unresectable Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
Interventions
BNT113Biological
IV injection
PembrolizumabBiological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumabTime frame: up to 27 months
- Part B - Overall survival (OS)Time frame: up to 48 months
- Part B - Progression-free survival (PFS)Time frame: up to 48 months
Locations
136 sites in 21 countries. Site status is shown where the registry gives one.
UCLA Cancer Care
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
Yale University
New Haven, Connecticut
The George Washington Cancer Center
Washington D.C., District of Columbia
University of Miami Miller School of Medicine
Miami, Florida
Winship Cancer Institute
Atlanta, Georgia
Norton Cancer Institute
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
The University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Memorial Sloan Kettering Cancer Center
Long Island City, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Montefiore Medical Center
The Bronx, New York
University of Cincinnati Cancer Center
Cincinnati, Ohio
MD Anderson Cancer Center
Houston, Texas
Centro de Oncología e Investigación Buenos Aires COIBA
Berazategui, Argentina
Instituto de Oncologia de Cordoba
Córdoba, Argentina
Centro Oncologico Riojano Integral
La Rioja, Argentina
Centro de Investigacion Pergamino SA - Clinica Pergamino
Pergamino, Argentina
Instituto de Oncologia de Rosario
Rosario, Argentina
Sanatorio Britanico
Rosario, Argentina
CAIPO Centro para la Atencion Integral del Paciente Oncologico
San Miguel de Tucumán, Argentina
Cancer Research SA
Adelaide, Australia
Flinders Medical Centre
Bedford Park, Australia
St Vincent's Hospital
Fitzroy, Australia
Royal North Shore Hospital
Saint Leonards, Australia
John Flynn Private Hospital
Tugun, Australia
Southern Medical Day Care Centre
Wollongong, Australia
LKH - Univ. Klinikum Graz
Graz, Austria
Landeskrankenhaus/ Univ.-Kliniken Innsbruck
Innsbruck, Austria
HNO, Kopf-und Halschirurgie Ordensklinikum Linz Barmherzigen Schwestern
Linz, Austria
Uniklinikum Salzburg, Univ. Klinik fur Innere Medizin III
Salzburg, Austria
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Gent UZ Gent
Ghent, Belgium
Fundação PIO XII - Hospital de Amor Barretos
Barretos, Brazil
Oncocentro - Grupo Oncoclinicas
Belo Horizonte, Brazil
Fundacao Universidade de Caxias do Sul - Instituto de Pesquisas em Saude IPS-UCS
Caxias do Sul, Brazil
Hospital Erasto Gaertner
Curitiba, Brazil
Oncosite - Centro de Pesquisa Clinica em Oncologia
Ijuí, Brazil
Hospital Marcio Cunha
Ipatinga, Brazil
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.